Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Tanzania president remorseful over internet shutdown on election day - 2Iran executes two men who tried storming military facility during January protest crackdown
- 3RSF attack on Sudan’s South Kordofan kills at least 14, including children
- 4Flash flooding causes highways to close to and from Eilat
- 5True to life Authenticity d: A Survey of \Certifiable Stories\ Narrative
- The most effective method to Shield Your Gold Ventures: Procedures and Precautionary measures
- Watch live as near-Earth asteroid Eros buzzes the Andromeda Galaxy on Nov. 30 (video)
- Slovakia rejects EU call to scrap higher fuel prices for foreign cars
- Must-Sit in front of the Programs from Europe and the US
- EU health regulator urges immediate vaccinations amid early surge in flu cases
- Major railway disruptions persist as Germany braces for more snow
- Artemis II crew take new photo of far side of the moon
- Inside the cockpit of RAF tanker during defensive mission against Iranian drones
- 'Here we go again': Businesses grapple with fuel costs
